Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8821211 | 1.00 | FOLH1 (0.53) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL8821210 | 1.00 | FOLH1 (0.53) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL4299646 | 0.98 | FOLH1 (0.54) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL15756737 | 0.98 | FOLH1 (0.54) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL27204494 | 0.94 | FOLH1 (0.48) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL27164811 | 0.94 | FOLH1 (0.48) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL30932293 | 0.93 | FOLH1 (0.49) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| Glycylglycylglycine SCHEMBL2567025 | 0.93 | FOLH1 (0.52) | FOLH1SLC6A5SLC15A2CPB2GNPAT | |
| SCHEMBL30455335 | 0.91 | NMT1 (0.50) | FOLH1SLC6A5SLC15A2 | |
| SCHEMBL32672545 | 0.89 | NMT1 (0.51) | FOLH1SLC6A5SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | BeijingGiluntidePharmaceuticalCo.,Ltd. (CN) | 2025-09-25 | — | — | US | disclosed |
| US-12357712-B2 | Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy | BEIJING GILUNTIDE PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| US-12180299-B2 | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use | ADIMAB, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-12181480-B2 | Polyspecificity reagents, methods for their preparation and use | ADIMAB, LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-3280444-B1 | METHODS FOR PURIFYING HETERODIMERIC MULTISPECIFIC ANTIBODIES FROM PARENTAL HOMODIMERIC ANTIBODY SPECIES | ADIMAB LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20230117927-A1 | Targeted Radiopharmaceutical for Tumor and Its Use in the Imaging-guided Combination Therapy of Targeted Radiotherapy and Immunotherapy | BEIJING GILUNTIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230115655-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | ASTRAZENECA PHARMACEUTICALS LP | 2023-04-13 | — | — | US | disclosed |
| CN-108472360-B | Method for purifying heterodimeric multispecific antibodies from parent homodimeric antibody species | 阿迪马布有限责任公司 | 2023-01-17 | — | — | CN | disclosed |
| US-11535659-B2 | Engineered polypeptides having enhanced duration of action | AMRYT PHARMACEUTICALS INC. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4050026-A1 | METHOD OF OBTAINING OR IDENTIFYING ONE OR MORE COMMON LIGHT CHAINS FOR USE IN PREPARING A MULTISPECIFIC ANTIBODY | Adimab, LLC (US) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | CD274, ITGB1, ITGA1 | FOLH1 316/4885SLC6A5 4809/4885SLC15A2 4403/4885 |
| US-20230115655-A1 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION | IAPP, HDGF, FABP1 | FOLH1 211/4885SLC6A5 4657/4885SLC15A2 1885/4885 |
| US-11535659-B2 | Engineered polypeptides having enhanced duration of action | IAPP, HDGF, FABP1 | FOLH1 211/4885SLC6A5 4657/4885SLC15A2 1885/4885 |
| US-12357712-B2 | Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy | CD274, ITGB1, ITGA1 | FOLH1 316/4885SLC6A5 4809/4885SLC15A2 4403/4885 |
| US-20230117927-A1 | Targeted Radiopharmaceutical for Tumor and Its Use in the Imaging-guided Combination Therapy of Targeted Radiotherapy and Immunotherapy | CD274, ITGB1, ITGA1 | FOLH1 316/4885SLC6A5 4809/4885SLC15A2 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.